Goldman Sachs
TXG icon

Goldman Sachs’s 10x Genomics TXG Stock Holding History

Goldman Sachs’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121M Sell
3,148,859
-822,941
-21% -$21.6M 0.01% 1100
2026
Q1 		$84.3M Buy
3,971,800
+884,533
+29% +$17.7M 0.01% 1161
2025
Q4 		$50.4M Buy
3,087,267
+411,940
+15% +$6.22M 0.01% 1503
2025
Q3 		$31.3M Buy
2,675,327
+2,067,562
+340% +$27M ﹤0.01% 1830
2025
Q2 		$7.04M Sell
607,765
-37,601
-6% -$343K ﹤0.01% 3093
2025
Q1 		$5.63M Buy
645,366
+400,430
+163% +$5.05M ﹤0.01% 3231
2024
Q4 		$3.52M Sell
244,936
-216,296
-47% -$3.41M ﹤0.01% 3794
2024
Q3 		$10.4M Buy
461,232
+205,869
+81% +$4.26M ﹤0.01% 2671
2024
Q2 		$4.97M Sell
255,363
-30,783
-11% -$806K ﹤0.01% 3158
2024
Q1 		$10.7M Sell
286,146
-86,727
-23% -$3.81M ﹤0.01% 2402
2023
Q4 		$20.9M Buy
372,873
+1,815
+0.5% +$79K ﹤0.01% 1838
2023
Q3 		$15.3M Sell
371,058
-297,471
-44% -$15.5M ﹤0.01% 2018
2023
Q2 		$37.3M Buy
668,529
+283,432
+74% +$15.3M 0.01% 1316
2023
Q1 		$21.5M Sell
385,097
-32,196
-8% -$1.5M ﹤0.01% 1759
2022
Q4 		$15.2M Sell
417,293
-98,393
-19% -$3.22M ﹤0.01% 2200
2022
Q3 		$14.7M Sell
515,686
-125,732
-20% -$4.79M ﹤0.01% 2140
2022
Q2 		$29M Sell
641,418
-44,852
-7% -$2.33M 0.01% 1588
2022
Q1 		$52.2M Buy
686,270
+485,997
+243% +$42.5M 0.01% 1238
2021
Q4 		$29.8M Sell
200,273
-18,589
-8% -$2.85M 0.01% 1770
2021
Q3 		$31.9M Sell
218,862
-317,619
-59% -$54.5M 0.01% 1641
2021
Q2 		$105M Buy
536,481
+30,436
+6% +$5.51M 0.02% 703
2021
Q1 		$91.6M Buy
506,045
+107,419
+27% +$18.5M 0.02% 707
2020
Q4 		$56.4M Sell
398,626
-3,408
-0.8% -$495K 0.01% 1037
2020
Q3 		$50.1M Buy
402,034
+42,411
+12% +$4.45M 0.01% 1000
2020
Q2 		$32.1M Buy
359,623
+178,469
+99% +$13.9M 0.01% 1303
2020
Q1 		$11.3M Buy
181,154
+81,798
+82% +$6.38M ﹤0.01% 1997
2019
Q4 		$7.58M Sell
99,356
-42,790
-30% -$2.57M ﹤0.01% 2644
2019
Q3 		$7.16M Buy
+142,146
New +$7.87M ﹤0.01% 2584

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's TXG Position: Q2 2026 in Review

Goldman Sachs reduced its 10x Genomics (TXG) stake by 21% in Q2 2026, selling an estimated $21.6M and leaving 3,148,859 shares worth $121M. The position accounts for 0.01% of the portfolio, ranked #1100.

Goldman Sachs first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Goldman Sachs held 3,148,859 shares of 10x Genomics worth $121M as of Q2 2026.
  • Goldman Sachs sold 822,941 10x Genomics shares in Q2 2026, an estimated $21.6M.
  • 10x Genomics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1100 holding.
  • Goldman Sachs first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.